Henry Feng, MD
Retina Specialist · Chicago, ILNPI 1538522834
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,326 of the $16,114 with a category attached, or 70.3%. 16 manufacturers reported payments, led by AbbVie at 56.0% of the total. Reporting peaked in 2024 at $12,527 and has fallen 96.5% since, to $433 in 2025.
Across 65 payments — averaging $247.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Regeneron$4K
- Alimera Sciences, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$598
- Alcon$525
- Genentech, Inc.$207
- plus $842 from 10 others
What the payments were for
- Consulting fees$11,32670%
- Speaking & faculty fees$1,2007%
- Travel & lodging$6274%
- Food & beverage$2,96118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $9,025 |
| Regeneron | 4 | $3,544 |
| Alimera Sciences, Inc. | 5 | $1,372 |
| Regeneron Healthcare Solutions, Inc. | 13 | $598 |
| Alcon | 5 | $525 |
| Genentech, Inc. | 2 | $207 |
| Astellas Pharma US Inc | 4 | $199 |
| Novartis | 1 | $107 |
| Eyepoint US, Inc. | 2 | $105 |
| Apellis Pharmaceuticals, Inc. | 4 | $103 |
| Gilead | 1 | $100 |
| Amgen | 3 | $67 |
| Genentech USA, Inc. | 2 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Biogen | 1 | $33 |
| Ocular Therapeutix, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$3,950
- EYLEA HD$3,457
- Iluvien$1,200
- EYLEA$331
- AcrySof IQ PanOptix$187
- Constellation$107
- XIIDRA$107
- Yescarta$100
How this compares
$16,114 in reported general payments places this provider in the 75th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 123 | $7,079 |
| Ketorolac Tromethamine | 65 | $1,405 |
| Atropine Sulfate | 16 | $640 |
| Ciprofloxacin Hcl | 22 | $317 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $290 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chicago
- Rahul KomatiChicago$143K
- Veena RaijiChicago$69K
- Jeffrey ParnellChicago$27K
- Paulpoj ChiranandChicago$17K
- Shaun IttiaraChicago$9K
- Sarah SyedaChicago$6K
- Saagar PanditChicago$6K
- Daniel BalikovChicago$3K
- Emily ShepherdChicago$3K
- John WilguckiChicago$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.